NGM-708

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNGM-708
Drug Alias NameNGM-708
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor B1 inhibitorsLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor B1Leukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNGM Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A